Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,701 | $2,324 | $5,580 | $24,105 |
| - Cash | $1,964 | $4,870 | $14,075 | $17,374 |
| + Debt | $2,086 | $20,561 | $21,542 | $29,233 |
| Enterprise Value | $2,823 | $18,015 | $13,047 | $35,964 |
| Revenue | $658 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$580 | -$513 | -$560 | -$748 |
| % Margin | -88.1% | – | – | – |
| EBITDA | -$6,989 | -$9,192 | -$10,499 | -$10,391 |
| % Margin | -1,062.2% | – | – | – |
| Net Income | $4,796 | -$6,500 | -$5,796 | -$8,206 |
| % Margin | 728.9% | – | – | – |
| EPS Diluted | 6 | -16.8 | -30.8 | -80 |
| % Growth | 135.7% | 45.5% | 61.5% | – |
| Operating Cash Flow | -$6,335 | -$9,382 | -$7,265 | -$7,426 |
| Capital Expenditures | -$12 | -$637 | -$836 | -$133 |
| Free Cash Flow | -$6,347 | -$10,019 | -$8,101 | -$7,565 |